Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00277602 | Riluzole in Huntington's Disease | PHASE3 | COMPLETED | 537 | — | — | Nov 1, 1999 | Jul 1, 2004 | Feb 17, 2012 | - | — |
| Name | Type | Description |
|---|---|---|
| Riluzole | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of Huntington's disease and CAG repeat length of 36 or more * UHDRS Motor score of at least 5 points * UHDRS TFC score of at least 8 points, i.e. patients must be independently ambulatory and must not require nursing care * Females require a negative blood p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 2 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |